HRP20161397T1 - Plazmid bez antibiotika - Google Patents
Plazmid bez antibiotika Download PDFInfo
- Publication number
- HRP20161397T1 HRP20161397T1 HRP20161397TT HRP20161397T HRP20161397T1 HR P20161397 T1 HRP20161397 T1 HR P20161397T1 HR P20161397T T HRP20161397T T HR P20161397TT HR P20161397 T HRP20161397 T HR P20161397T HR P20161397 T1 HRP20161397 T1 HR P20161397T1
- Authority
- HR
- Croatia
- Prior art keywords
- host
- bacterial strain
- protein
- polynucleotide
- sequence
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 230000001580 bacterial effect Effects 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 6
- 230000001718 repressive effect Effects 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 3
- 101150025220 sacB gene Proteins 0.000 claims 3
- 241000701959 Escherichia virus Lambda Species 0.000 claims 2
- 210000003578 bacterial chromosome Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 101150112726 purN gene Proteins 0.000 claims 2
- 241001136161 Avibacterium Species 0.000 claims 1
- 241000589562 Brucella Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 206010017914 Gastroenteritis salmonella Diseases 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 241000606860 Pasteurella Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000607128 Salmonella enterica subsp. enterica serovar Infantis Species 0.000 claims 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012907 medicinal substance Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/73—Expression systems using phage (lambda) regulatory sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Claims (15)
1. Promijenjeni soj gram-negativne bakterije domaćina, putem inženjeringa, naznačen time, da obuhvaća plazmid bez ljekovite tvari, pri čemu spomenuti plazmid bez lijeka obuhvaća polinukleotid koji kodira cl represivni protein i ima najmanje 90% identiteta sekvence od polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:1, 45, 47, 49, 51, 53, 55, 57 ili 59, te pritom bakterija domaćin sadrži jednu ili više kopija heterolognog polinukleotida u netemeljnom području bakterijskog kromosoma, dok heterologni polinukleotid kodira proizvod koji nije toksičan za domaćina, gdje heterologni polinukleotid sadrži sacB gen koji kodira SacB protein koji ima najmanje 90% identiteta sekvence od polipeptida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:4, 60, 62, 64, 66, 68, 70, 72 ili 74, te time, da je heterologni polinukleotid funkcionalno povezan na promotor iz λ-faga koji sadrži sekvencu prikazanu u SEQ ID NO:5.
2. Bakterijski soj prema zahtjevu 1, naznačen time, da bakterija domaćin sadrži dvije ili više kopija heterolognog polinukleotida u netemeljnom području od bakterijskog kromosoma.
3. Soj bakterije domaćina prema zahtjevu 1 ili 2, naznačen time, da je bakterijski soj odabran iz skupine koju čine Avibacterium, Brucella, Escherichia coli, Haeomophilus (primjerice Haemophilus suis), Salmonella (primjerice Salmonella enteritis, Salmonella typhimurium, Salmonella infantis), Shigella, Pasteurella, i Rimeirella.
4. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 3, naznačen time, da netemeljno područje obuhvaća deA gen ili purN gen.
5. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 4, naznačen time, da sacB gen kodira SacB protein koji ima najmanje 90% identiteta sekvence od polipeptida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:4.
6. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 5, naznačen time, da bakterijski soj sadrži jednu ili više kopija polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:75.
7. Soj bakterije domaćina prema zahtjevu 6, naznačen time, da bakterijski soj sadrži dvije kopije polinukleotida od SEQ ID NO:75, pri čemu je jedna kopija umetnuta u deA gen i preostala kopija je umetnuta u purN gen od kromosoma domaćina.
8. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 7, naznačen time, da polinukleotid koji kodira cl represivni protein, kodira polipeptid koji ima najmanje 90% identiteta sekvence od polipeptida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:2, 44, 46, 48, 50, 52, 54, 56 ili 58.
9. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je polinukleotid koji kodira cl represivni protein, funkcionalno povezan na promotor.
10. Soj bakterije domaćina prema zahtjevu 9, naznačen time, da promotor koji je funkcionalno povezan na polinukleotid koji kodira cl represivni protein, jest P1 promotor ili je to urođeni cl promotor.
11. Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 10, naznačen time, da plazmid nadalje obuhvaća heterologni polinukleotid koji kodira imunogen ili protein.
12. Soj bakterije domaćina prema zahtjevu 11, naznačen time, da je heterologni polinukleotid od plazmida funkcionalno povezan na promotor koji djeluje u eukariotskim ili prokariotskim stanicama.
13. Soj bakterije domaćina prema zahtjevu 12, naznačen time, da je heterologni polinukleotid od plazmida funkcionalno povezan na CMV promotor ili na promotor koji je izoliran iz gram-negativne bakterije.
14. Postupak proizvodnje proteina ili imunogena, naznačen time, da obuhvaća sljedeće korake:
1) inženjering gram-negativnog soja bakterije domaćina koji obuhvaća heterologni polinukleotid umetnut putem alelne zamjene u jedno ili više netemeljnih područja od kromosoma domaćina, gdje spomenuti heterologni polinukleotid kodira proizvod koji nije toksičan za domaćina, pri čemu heterologni polinukleotid sadrži sacB gen koji kodira SacB protein koji ima najmanje 90% identiteta sekvence od polipeptida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:4, 60, 62, 64, 66, 68, 70, 72 ili 74, dok je heterologni polinukleotid funkcionalno povezan na promotor iz λ-faga, koji sadrži sekvencu prikazanu u SEQ ID NO:5;
2) izgradnja DNK plazmida koji sadrži polinukleotid koji kodira cl represivni protein koji ima najmanje 90% identiteta sekvence od polinukleotida koji sadrži sekvencu kao što je prikazano u SEQ ID NO:1, 45, 47, 49, 51, 53, 55, 57 ili 59, dok gen kodira imunogen ili protein;
3) pretvaranje soja bakterije domaćina s DNK plazmidom koji sadrži polinukleotid koji kodira cl represivni protein i gen koji kodira imunogen ili protein;
4) rast pretvorenog soja bakterije domaćina u prisutnosti sukroze na temperaturi u rasponu od 30°C do 42°C; i
(5) obnavljanje imunogena ili proteina.
15. Postupak prema zahtjevu 14, naznačen time, da je heterologni polinukleotid umetnut putem alelne zamjene u dva ili više netemeljnih područja od kromosoma domaćina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18075509P | 2009-05-22 | 2009-05-22 | |
| PCT/US2010/035979 WO2010135742A1 (en) | 2009-05-22 | 2010-05-24 | Antibiotic-free plasmid |
| EP10720510.6A EP2432884B1 (en) | 2009-05-22 | 2010-05-24 | Antibiotic-free plasmid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161397T1 true HRP20161397T1 (hr) | 2016-12-16 |
Family
ID=42342694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161397TT HRP20161397T1 (hr) | 2009-05-22 | 2016-10-25 | Plazmid bez antibiotika |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9217153B2 (hr) |
| EP (2) | EP2432884B1 (hr) |
| JP (2) | JP5918125B2 (hr) |
| KR (1) | KR101719833B1 (hr) |
| AU (1) | AU2010249325B2 (hr) |
| BR (1) | BRPI1011048B1 (hr) |
| CA (1) | CA2761964C (hr) |
| DK (1) | DK2432884T3 (hr) |
| ES (1) | ES2600612T3 (hr) |
| HR (1) | HRP20161397T1 (hr) |
| HU (1) | HUE031597T2 (hr) |
| LT (1) | LT2432884T (hr) |
| MX (1) | MX2011012234A (hr) |
| NZ (1) | NZ596453A (hr) |
| PL (1) | PL2432884T3 (hr) |
| PT (1) | PT2432884T (hr) |
| RU (1) | RU2548809C2 (hr) |
| SI (1) | SI2432884T1 (hr) |
| WO (1) | WO2010135742A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013141823A1 (en) | 2011-12-21 | 2013-09-26 | Bionet-Asia, Co. Ltd | Modified bordetella pertussis strains |
| WO2015089707A1 (zh) * | 2013-12-16 | 2015-06-25 | 财团法人农业科技研究所 | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 |
| WO2016012607A1 (en) * | 2014-07-25 | 2016-01-28 | Delphi Genetics | Improved host cell for producing proteins |
| CN109922827B (zh) * | 2016-11-01 | 2024-03-01 | 诺和诺德股份有限公司 | 致耐受性dna疫苗 |
| RU2705252C1 (ru) * | 2018-06-08 | 2019-11-06 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген CFTR, или NOS1, или AQ1, или AQ3, или AQ5, для лечения заболеваний, связанных с необходимостью повышения уровня экспрессии этих целевых генов, способ его получения и использования, штамм Escherichia coli SCS110-AF/VTvaf17-CFTR, или Escherichia coli SCS110-AF/VTvaf17-NOS1, или Escherichia coli SCS110-AF/VTvaf17-AQ1, или Escherichia coli SCS110-AF/VTvaf17-AQ3, или Escherichia coli SCS110-AF/VTvaf17-AQ5, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2712838C1 (ru) * | 2018-09-04 | 2020-01-31 | Генетик Диагностик Энд Терапи 21 Лтд | Генотерапевтический ДНК-вектор GDTT1.8NAS12, способ его получения, штамм Escherichia coli JM110-NAS, способ его получения, штамм Escherichia coli JM110-NAS/GDTT1.8NAS12, несущий генотерапевтический ДНК-вектор GDTT1.8NAS12, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| WO2020050744A1 (en) * | 2018-09-04 | 2020-03-12 | Obschestvo S Ogranichennoi Otvetstvennostju "Allel Tsentr Innovatsionnykh Biotekhnology" | Gene therapy based on vector vtvaf17 |
| RU2705256C1 (ru) * | 2018-09-05 | 2019-11-06 | Общество С Ограниченной Ответственностью "Прорывные Инновационные Технологии" | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов SKI, TGFB3, TIMP2, FMOD для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-SKI или Escherichia coli SCS110-AF/VTvaf17-TGFB3 или Escherichia coli SCS110-AF/VTvaf17-TIMP2 или Escherichia coli SCS110-AF/VTvaf17-FMOD, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2730664C2 (ru) * | 2018-12-27 | 2020-08-24 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов ANG, ANGPT1, VEGFA, FGF1, HIF1α, HGF, SDF1, KLK4, PDGFC, PROK1, PROK2 для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-ANG, или Escherichia coli SCS110-AF/VTvaf17-ANGPT1, или Escherichia coli SCS110-AF/VTvaf17-VEGFA, или Escherichia coli SCS110-AF/VTvaf17-FGF1, или Escherichia coli SCS110-AF/VTvaf17-HIF1α, или Escherichia coli SCS110-AF/VTvaf17-HGF, или Escherichia coli SCS110-AF/VTvaf17-SDF1, или Escherichia coli SCS110-AF/VTvaf17-KLK4, или Escherichia coli SCS110-AF/VTvaf17-PDGFC, или Escherichia coli SCS110-AF/VTvaf17-PROK1, или Escherichia coli SCS110-AF/VTvaf17-PROK2, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| RU2715314C1 (ru) * | 2019-01-25 | 2020-02-26 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор VTvaf17-Act1-Cas9 на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген Cas9, для гетерологичной экспрессии этого целевого гена в клетках растений при геномном редактировании растений, способ получения и применения генотерапевтического ДНК-вектора, штамм Escherichia coli SCS110-AF/VTvaf17-Act1-Cas9, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
| US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
| WO2021240039A1 (es) | 2020-05-28 | 2021-12-02 | Consejo Superior De Investigaciones Científicas (Csic) | Replicones de arn de coronavirus y su uso como vacunas |
| EP4019539A1 (en) * | 2020-12-22 | 2022-06-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Recombinant bacterium and uses thereof |
| WO2023094595A1 (en) | 2021-11-26 | 2023-06-01 | Consejo Superior De Investigaciones Científicas | Coronavirus derived rna replicons and their use as vaccines |
| WO2024096123A1 (ja) * | 2022-11-04 | 2024-05-10 | 株式会社バイオパレット | 遺伝子が改変された微生物およびその生産方法 |
| CN118374547A (zh) * | 2023-01-13 | 2024-07-23 | 上海吉量医药工程有限公司 | 一种无抗微质粒及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4506013A (en) * | 1980-10-03 | 1985-03-19 | Eli Lilly And Company | Stabilizing and selecting recombinant DNA host cells |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5059529A (en) | 1984-08-27 | 1991-10-22 | Bio-Technology General Corp. | Stabilized expression vectors containing λPL promoter and the gene for the cI434 repressor, plasmids containing the vectors, hosts containing the plasmids and related methods |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
| IE872455L (en) | 1986-09-12 | 1988-03-12 | Lanstrase Ltd | Improved recombinant expression |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
| US5300431A (en) * | 1991-02-26 | 1994-04-05 | E. I. Du Pont De Nemours And Company | Positive selection vector for the bacteriophage P1 cloning system |
| CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| EP0963439B1 (en) * | 1997-02-19 | 2007-04-11 | Enol Energy Inc. | Genetically modified cyanobacteria for the production of ethanol |
| AU6511000A (en) * | 1999-08-02 | 2001-02-19 | Baylor College Of Medicine | Novel vectors and system for selectable targeted integration of transgenes into a chromosome without antibiotic resistance markers |
| GB0211459D0 (en) | 2002-05-18 | 2002-06-26 | Cobra Therapeutics Ltd | Plasmid stabilisation in vivo |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| TWI311152B (en) * | 2004-09-17 | 2009-06-21 | Boehringer Ingelheim Rcv Gmbh & Co K | Host-vector system for antibiotic-free cole1 plasmid propagation |
| RU2312146C1 (ru) * | 2006-03-30 | 2007-12-10 | Николай Викторович Равин | Вектор на основе репликона бактериофага n15 и рекомбинантный вектор для регулируемой экспрессии целевого гена в клетках escherichia coli, штамм escherichia coli, обеспечивающий возможность регуляции числа копий вектора, и система экспрессии |
-
2010
- 2010-05-24 ES ES10720510.6T patent/ES2600612T3/es active Active
- 2010-05-24 KR KR1020117030800A patent/KR101719833B1/ko active IP Right Grant
- 2010-05-24 US US12/786,186 patent/US9217153B2/en active Active
- 2010-05-24 WO PCT/US2010/035979 patent/WO2010135742A1/en active Application Filing
- 2010-05-24 SI SI201031305A patent/SI2432884T1/sl unknown
- 2010-05-24 DK DK10720510.6T patent/DK2432884T3/en active
- 2010-05-24 EP EP10720510.6A patent/EP2432884B1/en active Active
- 2010-05-24 PL PL10720510T patent/PL2432884T3/pl unknown
- 2010-05-24 EP EP16164124.6A patent/EP3124613B1/en active Active
- 2010-05-24 BR BRPI1011048A patent/BRPI1011048B1/pt active IP Right Grant
- 2010-05-24 MX MX2011012234A patent/MX2011012234A/es active IP Right Grant
- 2010-05-24 AU AU2010249325A patent/AU2010249325B2/en active Active
- 2010-05-24 CA CA2761964A patent/CA2761964C/en active Active
- 2010-05-24 NZ NZ596453A patent/NZ596453A/xx unknown
- 2010-05-24 PT PT107205106T patent/PT2432884T/pt unknown
- 2010-05-24 RU RU2011152377/10A patent/RU2548809C2/ru active
- 2010-05-24 JP JP2012512086A patent/JP5918125B2/ja active Active
- 2010-05-24 LT LTEP10720510.6T patent/LT2432884T/lt unknown
- 2010-05-24 HU HUE10720510A patent/HUE031597T2/en unknown
-
2015
- 2015-08-26 JP JP2015166767A patent/JP2015221050A/ja active Pending
- 2015-11-03 US US14/930,710 patent/US10487334B2/en active Active
-
2016
- 2016-10-25 HR HRP20161397TT patent/HRP20161397T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2432884B1 (en) | 2016-08-03 |
| BRPI1011048B1 (pt) | 2019-01-29 |
| PT2432884T (pt) | 2016-10-06 |
| MX2011012234A (es) | 2012-03-07 |
| CN102482679A (zh) | 2012-05-30 |
| LT2432884T (lt) | 2016-11-10 |
| US10487334B2 (en) | 2019-11-26 |
| US20100298419A1 (en) | 2010-11-25 |
| RU2548809C2 (ru) | 2015-04-20 |
| EP2432884A1 (en) | 2012-03-28 |
| KR20120016661A (ko) | 2012-02-24 |
| KR101719833B1 (ko) | 2017-03-24 |
| WO2010135742A1 (en) | 2010-11-25 |
| EP3124613A1 (en) | 2017-02-01 |
| CA2761964A1 (en) | 2010-11-25 |
| US20160312231A1 (en) | 2016-10-27 |
| SI2432884T1 (sl) | 2016-11-30 |
| HUE031597T2 (en) | 2017-07-28 |
| PL2432884T3 (pl) | 2017-01-31 |
| BRPI1011048A2 (pt) | 2016-08-02 |
| ES2600612T3 (es) | 2017-02-10 |
| JP2015221050A (ja) | 2015-12-10 |
| CA2761964C (en) | 2018-11-27 |
| US9217153B2 (en) | 2015-12-22 |
| AU2010249325A1 (en) | 2011-12-08 |
| JP5918125B2 (ja) | 2016-05-18 |
| NZ596453A (en) | 2013-09-27 |
| JP2012527249A (ja) | 2012-11-08 |
| RU2011152377A (ru) | 2013-06-27 |
| AU2010249325B2 (en) | 2014-12-18 |
| EP3124613B1 (en) | 2020-03-11 |
| DK2432884T3 (en) | 2016-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161397T1 (hr) | Plazmid bez antibiotika | |
| CN110325545B (zh) | 基于减毒细菌的蛋白递送 | |
| Wagner et al. | Small RNAs in bacteria and archaea: who they are, what they do, and how they do it | |
| EP3225690B1 (en) | Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use thereof | |
| Dietz et al. | Identification of target genes regulated by the two-component system HP166-HP165 of Helicobacter pylori | |
| Sandkvist et al. | Secretion of recombinant proteins by Gram-negative bacteria | |
| Thomas et al. | Characterization of flagellum gene families of methanogenic archaea and localization of novel flagellum accessory proteins | |
| Vanderpool et al. | Heme-responsive transcriptional activation of Bordetella bhu genes | |
| Arenas et al. | Identification of conditionally essential genes for Streptococcus suis infection in pigs | |
| Möller et al. | Profound impact of Hfq on nutrient acquisition, metabolism and motility in the plant pathogen Agrobacterium tumefaciens | |
| Egan et al. | A GntR-type transcriptional repressor controls sialic acid utilization in Bifidobacterium breve UCC2003 | |
| Zhao et al. | A 3′ UTR-derived non-coding RNA RibS increases expression of cfa and promotes biofilm formation of Salmonella enterica serovar Typhi | |
| Müller et al. | Differential effects and interactions of endogenous and horizontally acquired H‐NS‐like proteins in pathogenic Escherichia coli | |
| Lan et al. | Comparison of two major forms of the Shigella virulence plasmid pINV: positive selection is a major force driving the divergence | |
| Cummins et al. | A mariner transposon-based signature-tagged mutagenesis system for the analysis of oral infection by Listeria monocytogenes | |
| Funahashi et al. | Characterization of a gene encoding the outer membrane receptor for ferric enterobactin in Aeromonas hydrophila ATCC 7966T | |
| Huang et al. | Role of yoaE Gene Regulated by CpxR in the Survival of Salmonella enterica Serovar Enteritidis in Antibacterial Egg White | |
| Xu et al. | A mutation in rcsB, a gene encoding the core component of the Rcs cascade, enhances the virulence of Edwardsiella tarda | |
| Kuan et al. | Arginine within a specific motif near the N‐terminal of FimY is critical for the maximal production of type 1 fimbriae in Salmonella enterica serovar Typhimurium | |
| HRP20161234T1 (hr) | Cjepiva koja sadrže toplinski osjetljive transgene | |
| Salvail et al. | Differential synthesis of novel small protein times Salmonella virulence program | |
| TWI486356B (zh) | 生產忌熱毒素ｂ次單元的質體、方法及其套組 | |
| Eum et al. | Complete genome sequence of Ligilactobacillus agilis LDTM47, bacteriocin-producing lactic acid bacteria isolated from broiler gastrointestinal tract | |
| Gulliver | The exploration of small RNA regulation in Pasteurella multocida | |
| EA044058B1 (ru) | Доставка белков на основе бактерий, аттенуированных по вирулентности |